Comparison of lanthascreen Eu kinase binding assay and surface plasmon resonance method in elucidating the binding kinetics of focal adhesion kinase inhibitors

Assay and Drug Development Technologies

Volumn 10, Issue 5, 2012, Pages 468-475

  Mason, Jennifer L ^a   Spais, Chrysanthe ^a   Husten, Jean ^a   Prouty, Eric ^a   Albom, Mark S ^a   Meyer, Sheryl L ^a   Ator, Mark A ^a   Angeles, Thelma S ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; BINDING ASSAY; BINDING KINETICS; BIOSENSOR; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; INTERMETHOD COMPARISON; LANTHASCREEN EU KINASE BINDING ASSAY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN INTERACTION; REFRACTION INDEX; SURFACE PLASMON RESONANCE;

FOCAL ADHESION KINASE 1; HUMANS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; STAUROSPORINE; SURFACE PLASMON RESONANCE;

EID: 84867273882     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2012.453     Document Type: Article

References (37)

1. Mira SK, Hanson DA, Schlaepfer DD: Focal adhesion kinase: In command and control of cell motility. Nat Rev Mol Cell Biol 2005;6:56-68. (Pubitemid 40064899)
2. Parsons JT: Focal adhesion kinase: The first ten years. J Cell Sci 2003;116:1409- 1416. (Pubitemid 36527488)
3. Fashena SJ, Thomas SM: Signaling by adhesion receptors. Nat Cell Biol 2000;2:E225-E229.
4. Schwartz MA, Ginsberg MH: Networks and crosstalk: Integrin signaling spreads. Nat Cell Biol 2002;4:E65-E68. (Pubitemid 34308840)
5. Zhao J, Guan J-L: Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 2009;28:35-49.
6. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, et al.: Expression profiling of serous low malignant potential, low-grade, and highgrade tumors of the ovary. Cancer Res 2005;65:10602-10612. (Pubitemid 41743756)
7. Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, et al.: Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: Correlation with preinvasive and invasive phenotypes. Clin Cancer Res 2000;6:2417-2423. (Pubitemid 30399210)
8. Carelli S, Zadra G, Vaira V, Falleni M, Bottiglieri L, Nosotti M, et al.: Upregulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer 2006;53:263-271. (Pubitemid 44209282)
9. Golubovskaya VM, Kweh FA, Cance WG: Focal adhesion kinase and cancer. Histol Histopathol 2009;24:503-510.
10. Han NM, Fleming RY, Curley SA, Gallick GE: Overexpression of focal adhesion kinase (p125FAK) in human colorectal carcinoma liver metastases: Independence from c-src or c-yes activation. Ann Surg Oncol 1997;4:264-268. (Pubitemid 127725254)
11. Owens LV, Xu L, Dent GA, Yang X, Sturge GC, Craven RJ, et al.: Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol 1996;3:100-105. (Pubitemid 126729497)
12. Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chevalier S: Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50 CSK in human metastatic prostate carcinoma. Int J Cancer 1996;68:164-171. (Pubitemid 26380117)
13. Halder J, Kamat AA, Landen CN, Jr., Han LY, Lutgendorf SK, Lin YG, et al.: Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-4924. (Pubitemid 44338579)
14. Han EK-H, McGonigal T: Role of focal adhesion kinase in human cancer: A potential target for drug discovery. Anti-Cancer Agents Med Chem 2007;7:681- 684. (Pubitemid 350237772)
15. Kohno M, Hasegawa H, Miyake M, Yamamoto T, Fujita S: CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase. Int J Cancer 2002;97:336-343. (Pubitemid 34049024)
16. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, et al.: Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007;67:10976-10983. (Pubitemid 350145927)
17. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, et al.: Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF- 562,271. Cancer Res 2008;68:1935-1944. (Pubitemid 351416580)
18. Copeland RA, Pompliano DL, Meek TD: Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006;5:730-739. (Pubitemid 44323700)
19. Tummino PJ, Copeland RA: Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008;47:5481-5492. (Pubitemid 351711169)
20. Andersson K, Karlsson R, Lofas S, Franklin G, Hamalainen MD: Label-free kinetic binding data as a decisive element in drug discovery. Expert Opin Drug Discov 2006;1:439-446.
21. Nordin H, Jungnelius M, Karlsson R, Karlsson OP: Kinetic studies of small molecule interactions with protein kinases using biosensor technology. Anal Biochem 2005;340:359-368. (Pubitemid 40544876)
22. Lebakken CS, Riddle SM, Singh U, Frazee WJ, Eliason HC, Gao Y, et al.: Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform. J Biomol Screen 2009;14:924-935.
23. Myszka DG, He X, Dembo M, Morton TA, Goldstein B: Extending the range of rate constants available from BIACORE: Interpreting mass transport-influenced binding data. Biophys J 1998;75:583-594. (Pubitemid 28357501)
24. Goldstein B, Coombs D, He X, Pineda AR, Wofsy C: The influence of transport on the kinetics of binding to surface receptors: Application to cells and BIAcore. J Mol Recognit 1999;12:293-299. (Pubitemid 129708592)
25. Iwata H, Imamura S, Hori A, Hixon MS, Kimura H, Miki H: Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry 2011;50:738-751.
26. Swinney DC: The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel 2009;12:31-39.
27. Lu H, Tonge PJ: Drug-target residence time: Critical information for lead optimization. Curr Opin Chem Biol 2010;14:467-474.
28. Backes AC, Zech B, Felber B, Muller G: Small-molecule inhibitors binding to protein kinase. Part I: exceptions from the traditional pharmacophore approach of type I inhibition. Expert Opin Drug Discov 2008;3:1409-1425.
29. Backes AC, Zech B, Felber B, Muller G: Small-molecule inhibitors binding to protein kinase. Part II: The novel pharmacophore approach of type II and type III inhibition. Expert Opin Drug Discov 2008;3:1427-1449.
30. Liu Y, Gray NS: Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358-364. (Pubitemid 43936934)
31. Kufareva I, Abagyan R: Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J Med Chem 2008;51:7924- 7932.
32. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000;289:1938-1942.
33. Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, Froning KJ, et al.: A novel mode of binding of Gleevec is revealed by the structure of spleen tyrosine kinase. J Biol Chem 2004;279:55827-55832. (Pubitemid 40066590)
34. Han S, Mistry A, Chang JS, Cunningham D, Griffor M, Bonnette PC, et al.: Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design. J Biol Chem 2009;284:13193-13201.
35. Nowakowski J, Cronin CN, McRee DE, Knuth MW, Nelson CG, Sang B-C, et al.: Structures of the cancer-related Aurora-A, FAK and EphA protein kinases from nanovolume crystallography. Structure 2002;10:1659-1667. (Pubitemid 35452573)
36. Karlsson R, Katsamba PS, Nordin H, Pol E, Myszka DG: Analyzing a kinetic titration series using affinity biosensors. Anal Biochem 2006;349:136-147. (Pubitemid 43129567)
37. Lietha D, Eck MJ: Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One 2008;3:1-7.